Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3932898rdf:typepubmed:Citationlld:pubmed
pubmed-article:3932898lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0003286lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0042291lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0457454lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C1444662lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:3932898lifeskim:mentionsumls-concept:C0003299lld:lifeskim
pubmed-article:3932898pubmed:issue11lld:pubmed
pubmed-article:3932898pubmed:dateCreated1985-11-27lld:pubmed
pubmed-article:3932898pubmed:abstractTextWe studied the pharmacokinetics of valproic acid (VPA) in 11 children before and after discontinuance of enzyme-inducing antiepileptic drugs (AEDs). Valproic acid elimination half-life increased from 7.1 to 11.8 hours. Total and intrinsic VPA clearance decreased by approximately 40%. Valproic acid serum protein binding varied among patients from 7 to 23.8%, but was not altered by AEDs. Seizure control was maintained and mental status improved once all other AEDs were withdrawn. After discontinuation of enzyme-inducing AEDs, serum VPA concentrations can be maintained with a lower VPA dosage given less frequently.lld:pubmed
pubmed-article:3932898pubmed:languageenglld:pubmed
pubmed-article:3932898pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3932898pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3932898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3932898pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3932898pubmed:statusMEDLINElld:pubmed
pubmed-article:3932898pubmed:monthNovlld:pubmed
pubmed-article:3932898pubmed:issn0028-3878lld:pubmed
pubmed-article:3932898pubmed:authorpubmed-author:CloydJ CJClld:pubmed
pubmed-article:3932898pubmed:authorpubmed-author:KrielR LRLlld:pubmed
pubmed-article:3932898pubmed:authorpubmed-author:FischerJ HJHlld:pubmed
pubmed-article:3932898pubmed:issnTypePrintlld:pubmed
pubmed-article:3932898pubmed:volume35lld:pubmed
pubmed-article:3932898pubmed:ownerNLMlld:pubmed
pubmed-article:3932898pubmed:authorsCompleteYlld:pubmed
pubmed-article:3932898pubmed:pagination1623-7lld:pubmed
pubmed-article:3932898pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:meshHeadingpubmed-meshheading:3932898-...lld:pubmed
pubmed-article:3932898pubmed:year1985lld:pubmed
pubmed-article:3932898pubmed:articleTitleValproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy.lld:pubmed
pubmed-article:3932898pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3932898pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3932898lld:pubmed